

SAMPLE — NOT LEGAL ADVICE. This response letter was generated automatically from publicly available analysis. It has NOT been reviewed by a licensed attorney and SHOULD NOT BE SENT to any party without substantial review and customization by qualified patent counsel. Use as a starting point only.

[Your Name]

[Your Title]

[Your Company]

[Street Address, City, State ZIP]

May 14, 2026

[Opposing Counsel Name]

[Firm Name]

[Address]

Re: U.S. Patent No. 11738124 — Response to Assertion of Infringement

Dear Counsel,

We acknowledge receipt of your correspondence asserting infringement of U.S. Patent No. 11738124 (the "11738124 Patent"). After preliminary review, we have substantial concerns about the validity, enforceability, and scope of the asserted claims, summarized below. We reserve all rights and defenses.

1. Subject Patent — Summary

Technical Analysis of U.S. Patent 11,738,124

Date of Analysis: May 13, 2026

This report provides a concise summary of United States Patent 11,738,124, including its key bibliographic details and a plain-language overview of its independent claims.

Bibliographic Information

- Title: System and method for collecting plasma.
- Assignee: Haemonetics Corporation.
- Inventor: Michael Ragusa.
- Filing Date: September 13, 2022.
- Issue Date: August 29, 2023.
- Abstract: A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a...

2. Validity Concerns under 35 U.S.C. § 102 — Prior Art

We have identified prior-art references that, in our preliminary view, anticipate one or more asserted claims of the 11738124 Patent:

Analysis of Prior Art for U.S. Patent 11,738,124

This analysis identifies and evaluates the most relevant prior art cited during the prosecution of U.S. Patent 11,738,124 ("the '124 patent"). The focus is on references that could potentially anticipate the patent's claims under 35 U.S.C. § 102, which pertains to novelty. The '124 patent, assigned to Haemonetics Corporation, claims a system and method for collecting a target volume of "pure plasma" by calculating and subtracting the volume of anticoagulant from the total collected volume, based on the donor's hematocrit.

The following prior art references are deemed most relevant to the core inventive concept of the '124 patent. This is not an exhaustive list of all citations but represents the patents that most closely describe the claimed invention.

1. U.S. Patent 5,681,273 A (Loken et al.)

- Full Citation: US 5,681,273 A, "Systems and methods for predicting blood processing parameters"
- Assignee: Baxter International Inc.
- Filing Date: December 23, 1991
- Publication Date: October 28, 1997
- Brief Description: This...

3. Obviousness under 35 U.S.C. § 103

Independent of § 102, we believe the asserted claims are obvious in view of combinations of prior art that a person having ordinary skill in the art would have been motivated to combine:

Obviousness Analysis of U.S. Patent 11,738,124

Date of Analysis: May 13, 2026

Standard: An invention is unpatentable if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (PHOSITA). This analysis is based on prior art available before the patent's priority date of May 30, 2017.

Analysis of Independent Claim 1 (Method) and Claim 11 (System)

The independent claims of U.S. Patent 11,738,124 are directed to a method and system for plasma collection where the key inventive concept is the calculation of the "pure plasma" volume collected by accounting for the volume of anticoagulant mixed in with the plasma, using the donor's hematocrit in the calculation, and stopping the procedure when a target volume of this pure plasma is reached.

The claims would have been obvious to a Person Having Ordinary Skill in the Art (PHOSITA) by combining the teachings of a standard automated apheresis system with the well-established...

4. Litigation History of the Patent

Public records reflect that the 11738124 Patent has been the subject of the following litigation, which informs our view of the asserted claims and your client's enforcement posture:

- Haemonetics Corporation v. Terumo BCT, Inc. — 1:25-cv-01409 · United States District Court for the District of Colorado · filed 2025-05-05 · Ongoing

• Terumo BCT, Inc. v. Haemonetics Corporation — IPR2025-01374 · USPTO Patent Trial and Appeal Board · filed 2025-08-04 · Pending

5. Request

In light of the foregoing, we request that your client (i) provide a detailed claim chart identifying each accused product or service and mapping every limitation of each asserted claim, (ii) identify any prior art known to your client, including any references cited during prosecution or reexamination, and (iii) substantiate the basis for any damages or licensing demand. We are prepared to discuss the matter further once we have received and reviewed the foregoing.

Sincerely,

[Your Name]

DISCLAIMER. This document is a machine-generated sample. The factual assertions, prior-art citations, and legal arguments above are AI-produced and may contain errors, omissions, or outdated information. Do not transmit this letter, in whole or in part, to any party. This is not legal advice; no attorney-client relationship is created by its existence. Consult a licensed patent attorney before responding to any patent-infringement assertion.

Generated May 14, 2026 by ihatepatenttrolls.com — sample only.